Rifabutin

Tuberculosis

Volumn 88, Issue 2, 2008, Pages 145-147

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

'RBT'; ALFACID; DRUG DERIVATIVE; ERYTHROMYCIN; ITRACONAZOLE; RIFABUTIN; RIFALAZIL; RIFAPENTINE;

ANOREXIA; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BIOLOGY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CORNEA DISEASE; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SOLUBILITY; HEARTBURN; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INDIGESTION; LUNG TOXICITY; MYCOBACTERIUM TUBERCULOSIS; MYOSITIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; SKIN DISCOLORATION; SKIN IRRITATION; THROMBOCYTOPENIA; TUBERCULOSIS; UVEITIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; HUMANS; RIFABUTIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43249113856     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70022-2     Document Type: Review

References (16)

1. Williams D., et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42 (1998) 1853-1857
2. Yang B., et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM- 1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 42 (1998) 621-628
3. Saribas Z., et al. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates. J Clin Microbiol 41 (2003) 816-818
4. Kunin C., et al. Antimicrobial activity of rifabutin. Clin Infect Dis 22 Suppl 1 (1996) S3-13 Discussion: S13-4
5. Bemer-Melchior P., et al. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 46 (2000) 571-576
6. Rastogi N., et al. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother 46 (2000) 565-570
7. Klemens S., et al. In vivo activities of newer rifamycin analogs against M. avium infection. Antimicrob Agents Chemother 35 (1991) 2026-2030
8. Araujo F., et al. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob Agents Chemother 40 (1996) 1335-1337
9. Ji B., et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 148 (1993) 1541-1546
10. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 49 9 (2000) 185-189. Available on-line at www.cdc.gov/nchstp/tb/
11. Benator D., et al. Clinical evaluation of the nelfinavir rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. Pharmacotherapy 27 (2007) 793-800
12. Weiner M., et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40 (2005) 1481-1491
13. Burman W., et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 173 (2006) 350-356
14. Burman W., et al. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 40 (2001) 327-341
15. 14C-rifabutin in animals and man. J Antimicrob Chemother 26 (1990) 813-822
16. Matteelli A., et al. Tolerability of twice-weekly rifabutin isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis 3 (2005) 1043-1046